JP2018513138A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513138A5 JP2018513138A5 JP2017550832A JP2017550832A JP2018513138A5 JP 2018513138 A5 JP2018513138 A5 JP 2018513138A5 JP 2017550832 A JP2017550832 A JP 2017550832A JP 2017550832 A JP2017550832 A JP 2017550832A JP 2018513138 A5 JP2018513138 A5 JP 2018513138A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- weight
- polyethylene glycol
- polyvinyl alcohol
- russia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 40
- 239000002552 dosage form Substances 0.000 claims description 32
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 26
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 26
- 239000007909 solid dosage form Substances 0.000 claims description 26
- 239000000014 opioid analgesic Substances 0.000 claims description 22
- 229960005070 ascorbic acid Drugs 0.000 claims description 20
- 235000010323 ascorbic acid Nutrition 0.000 claims description 20
- 239000011668 ascorbic acid Substances 0.000 claims description 20
- 239000002202 Polyethylene glycol Substances 0.000 claims description 15
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 229940050929 polyethylene glycol 3350 Drugs 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 239000008247 solid mixture Substances 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 4
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 4
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229960002085 oxycodone Drugs 0.000 claims description 4
- 229960005118 oxymorphone Drugs 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 238000009498 subcoating Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 11
- 239000007787 solid Substances 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562141981P | 2015-04-02 | 2015-04-02 | |
| US62/141,981 | 2015-04-02 | ||
| PCT/US2016/025176 WO2016161069A1 (en) | 2015-04-02 | 2016-03-31 | Combination dosage form of a mu opioid receptor antagonist and an opioid agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020016858A Division JP2020073583A (ja) | 2015-04-02 | 2020-02-04 | ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513138A JP2018513138A (ja) | 2018-05-24 |
| JP2018513138A5 true JP2018513138A5 (enExample) | 2019-03-14 |
| JP6713483B2 JP6713483B2 (ja) | 2020-06-24 |
Family
ID=55806767
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550832A Active JP6713483B2 (ja) | 2015-04-02 | 2016-03-31 | ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形 |
| JP2020016858A Withdrawn JP2020073583A (ja) | 2015-04-02 | 2020-02-04 | ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020016858A Withdrawn JP2020073583A (ja) | 2015-04-02 | 2020-02-04 | ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US20160287573A1 (enExample) |
| EP (1) | EP3277278B1 (enExample) |
| JP (2) | JP6713483B2 (enExample) |
| KR (1) | KR20170132325A (enExample) |
| CN (1) | CN107820424B (enExample) |
| AU (1) | AU2016243691A1 (enExample) |
| BR (1) | BR112017021120A2 (enExample) |
| CA (1) | CA2980328A1 (enExample) |
| CY (1) | CY1122828T1 (enExample) |
| DK (1) | DK3277278T3 (enExample) |
| ES (1) | ES2774473T3 (enExample) |
| HK (1) | HK1247105A1 (enExample) |
| HR (1) | HRP20200432T1 (enExample) |
| HU (1) | HUE048785T2 (enExample) |
| IL (1) | IL254593A0 (enExample) |
| LT (1) | LT3277278T (enExample) |
| ME (1) | ME03671B (enExample) |
| MX (1) | MX2017012474A (enExample) |
| PH (1) | PH12017501767A1 (enExample) |
| PL (1) | PL3277278T3 (enExample) |
| PT (1) | PT3277278T (enExample) |
| RS (1) | RS60074B1 (enExample) |
| RU (1) | RU2017134794A (enExample) |
| SI (1) | SI3277278T1 (enExample) |
| SM (1) | SMT202000157T1 (enExample) |
| TW (1) | TW201642856A (enExample) |
| WO (1) | WO2016161069A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2017134794A (ru) | 2015-04-02 | 2019-04-04 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | Комбинированная лекарственная форма антагониста мю-опиоидного рецептора и опиоидного средства |
| WO2019031560A1 (ja) * | 2017-08-08 | 2019-02-14 | 日本合成化学工業株式会社 | 医薬錠剤、およびその製造方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU773642C (en) | 1997-12-22 | 2006-04-06 | Mundipharma Pty Limited | Opioid agonist/antagonist combinations |
| US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| US6451806B2 (en) | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
| AR029538A1 (es) * | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
| US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
| NZ530971A (en) * | 2001-08-06 | 2004-08-27 | Euro Celtique S | Oral dosage forms comprising an opioid agonist with releasable and sequestered opioid antagonists |
| US20040224020A1 (en) * | 2002-12-18 | 2004-11-11 | Schoenhard Grant L. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
| US20050013863A1 (en) | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
| CN1897924B (zh) | 2003-09-26 | 2011-09-21 | 阿尔扎公司 | 能提供高载药量的药物包衣和提供它的方法 |
| TWI415635B (zh) | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
| WO2006094063A1 (en) | 2005-03-02 | 2006-09-08 | Theravance, Inc. | Quinolinone compounds as 5-ht4 receptor agonists |
| ES2366058T3 (es) * | 2006-03-01 | 2011-10-14 | Theravance, Inc. | Compuestos de 8-azabiciclo[3.2.1]octano como antagonistas de los receptores opioides mu. |
| MY145633A (en) | 2006-03-01 | 2012-03-15 | Theravance Inc | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| CN101500542A (zh) * | 2006-07-11 | 2009-08-05 | 共有药物有限公司 | 控释制剂 |
| TWI409067B (zh) * | 2007-02-28 | 2013-09-21 | Theravance Inc | ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型 |
| TWI415850B (zh) | 2007-07-20 | 2013-11-21 | Theravance Inc | 製備ｍｕ類鴉片受體拮抗劑之中間物的方法 |
| PL2294012T3 (pl) * | 2008-05-07 | 2014-12-31 | Salix Pharmaceuticals Inc | Podawanie środka czyszczącego jelito i antybiotyku w leczeniu choroby jelit |
| EP2210595A1 (en) | 2009-01-14 | 2010-07-28 | LEK Pharmaceuticals d.d. | Active coating of pharmaceutical dosage forms |
| MX2011011919A (es) * | 2009-05-12 | 2012-01-27 | Bpsi Holdings Llc | Sistemas de recubrimiento de pelicula de liberacion inmediata con barrera contra humedad mejorada y sustratos recubiertos con dichos sistemas. |
| IT1398930B1 (it) * | 2010-03-24 | 2013-03-28 | Molteni & C | Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi. |
| WO2012031124A2 (en) * | 2010-09-03 | 2012-03-08 | Bristol-Myers Squibb Company | Drug formulations using water soluble antioxidants |
| WO2012106303A1 (en) | 2011-02-01 | 2012-08-09 | Bristol-Myers Squibb Company | Pharmaceutical formulations including an amine compound |
| US9339489B2 (en) * | 2013-03-15 | 2016-05-17 | Aprecia Pharmaceuticals Company | Rapid disperse dosage form containing levetiracetam |
| RU2017134794A (ru) | 2015-04-02 | 2019-04-04 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | Комбинированная лекарственная форма антагониста мю-опиоидного рецептора и опиоидного средства |
-
2016
- 2016-03-31 RU RU2017134794A patent/RU2017134794A/ru not_active Application Discontinuation
- 2016-03-31 BR BR112017021120-3A patent/BR112017021120A2/pt not_active Application Discontinuation
- 2016-03-31 LT LTEP16718062.9T patent/LT3277278T/lt unknown
- 2016-03-31 AU AU2016243691A patent/AU2016243691A1/en not_active Abandoned
- 2016-03-31 US US15/086,816 patent/US20160287573A1/en not_active Abandoned
- 2016-03-31 CA CA2980328A patent/CA2980328A1/en not_active Abandoned
- 2016-03-31 HK HK18106740.0A patent/HK1247105A1/zh unknown
- 2016-03-31 JP JP2017550832A patent/JP6713483B2/ja active Active
- 2016-03-31 KR KR1020177031800A patent/KR20170132325A/ko not_active Withdrawn
- 2016-03-31 WO PCT/US2016/025176 patent/WO2016161069A1/en not_active Ceased
- 2016-03-31 PL PL16718062T patent/PL3277278T3/pl unknown
- 2016-03-31 TW TW105110406A patent/TW201642856A/zh unknown
- 2016-03-31 RS RS20200315A patent/RS60074B1/sr unknown
- 2016-03-31 ME MEP-2020-48A patent/ME03671B/me unknown
- 2016-03-31 ES ES16718062T patent/ES2774473T3/es active Active
- 2016-03-31 CN CN201680019821.7A patent/CN107820424B/zh active Active
- 2016-03-31 DK DK16718062.9T patent/DK3277278T3/da active
- 2016-03-31 SM SM20200157T patent/SMT202000157T1/it unknown
- 2016-03-31 SI SI201630671T patent/SI3277278T1/sl unknown
- 2016-03-31 MX MX2017012474A patent/MX2017012474A/es unknown
- 2016-03-31 HU HUE16718062A patent/HUE048785T2/hu unknown
- 2016-03-31 PT PT167180629T patent/PT3277278T/pt unknown
- 2016-03-31 EP EP16718062.9A patent/EP3277278B1/en active Active
- 2016-03-31 HR HRP20200432TT patent/HRP20200432T1/hr unknown
-
2017
- 2017-09-19 IL IL254593A patent/IL254593A0/en unknown
- 2017-09-26 PH PH12017501767A patent/PH12017501767A1/en unknown
- 2017-10-31 US US15/798,647 patent/US10369142B2/en active Active
-
2019
- 2019-06-27 US US16/454,353 patent/US10946009B2/en active Active
-
2020
- 2020-02-04 JP JP2020016858A patent/JP2020073583A/ja not_active Withdrawn
- 2020-03-17 CY CY20201100246T patent/CY1122828T1/el unknown
-
2021
- 2021-02-08 US US17/248,787 patent/US11452723B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2127587C1 (ru) | Устойчивые лекарственные формы с регулируемым выделением, имеющие акриловые полимерные покрытия, (варианты) и способ их получения | |
| JP2008280351A5 (enExample) | ||
| CA2561109A1 (en) | Gastric retention system | |
| JPS61176521A (ja) | 投与形態物の処理方法 | |
| JP2010510260A5 (enExample) | ||
| BR112016001822B1 (pt) | Comprimido farmacêutico compreendendo ácido acetilsalicílico e clopidogrel e seu processo de fabricação | |
| JP2018514523A5 (enExample) | ||
| JP2014503523A5 (enExample) | ||
| JP2016515523A5 (enExample) | ||
| RU2013141534A (ru) | Составы l-ментола, состоящие из множества частиц, и связанные с ними способы | |
| JP2010540547A5 (enExample) | ||
| CN108367078A (zh) | 医药微丸的干粉包衣组合物 | |
| AR103981A1 (es) | Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención | |
| BR112018001859B1 (pt) | Comprimido, e, método para produzir um comprimido | |
| HRP20211269T1 (hr) | Kompozicije prolijeka na bazi monometil fumarata | |
| CZ2015272A3 (cs) | Polymerní film s obsahem fotosensitizérů a jeho použití | |
| WO2016142708A3 (en) | Pharmaceutical composition | |
| WO2012053785A3 (ko) | 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛 | |
| JP2015508411A5 (enExample) | ||
| Osei-Yeboah et al. | A top coating strategy with highly bonding polymers to enable direct tableting of multiple unit pellet system (MUPS) | |
| JP2018513138A5 (enExample) | ||
| Muschert et al. | Improved long term stability of aqueous ethylcellulose film coatings: importance of the type of drug and starter core | |
| JP5973170B2 (ja) | 固体分子分散物 | |
| JP2015120758A5 (enExample) | ||
| JP2016033133A5 (enExample) |